Poster Presentations: AASLD Liver Meeting 2017

At the AASLD Liver Meeting this year, the following presentations were conducted by our distinguished partner and collaborator respectively:

Detailed Analysis of the Antifibrotic Effect of INT-767, a Dual FXR/TGR5 Agonist in an Obese Mouse Model of Diet-induced and Biopsy-confirmed NASH

By Dr Mathieu Petitjean, CEO, MedNest, USA

The farnesoid X receptor (FXR) and G protein coupled receptor (GPCR) TGR5 have been implicated in the regulation of metabolism, inflammation and fibrosis in non-alcoholic steatohepatitis (NASH). A dual FXR/TGR5 agonist, INT-767, has been developed and is in early clinical development. 

Application of Human NASH-based Transcriptome and Metabolome Profiles in Preclinical Models

By Dr Martine Morrison, TNO, Metabolic Health Research, The Netherlands

Dr. Morrison presented on the representation of human-based molecular disease profiles in an established pre-clinical model for NASH research - the Ldlr-/-.Leiden mouse – and the translational value of this model for the study of NASH-associated hepatic fibrosis.